PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, ...

Core Viewpoint - Nanobiotix is making significant progress in its clinical development programs, particularly with JNJ-1900 (NBTXR3), and is optimistic about upcoming milestones in cancer treatment [2][5]. Operational Highlights - The company is advancing the NANORAY-312 program in head and neck cancer and has expanded development into lung cancer through the CONVERGE study [2][6]. - The first patient has been dosed in the Phase 2 randomized CONVERGE study for unresectable stage 3 non-small cell lung cancer (NSCLC) [6][7]. - Clinical data presented at major conferences supports the expansion of JNJ-1900 into additional cancer indications, including lung cancer and locally advanced pancreatic cancer [2][6][7]. Financial Updates - As of March 31, 2025, Nanobiotix reported cash and cash equivalents of €39.8 million, which is expected to fund operations into mid-2026 [5][6]. - An amendment to the global licensing agreement for JNJ-1900 has extended the cash runway and reduced operational cash burn [6][7]. Product Overview - JNJ-1900 (NBTXR3) is a novel oncology product utilizing hafnium oxide nanoparticles, designed to induce tumor cell death when activated by radiotherapy [8][9]. - The product is being evaluated across multiple solid tumor indications and has received Fast Track designation from the FDA for specific cancer treatments [9][10]. Collaboration and Strategy - Nanobiotix has engaged in collaborations to expand the development of JNJ-1900, including a partnership with MD Anderson Cancer Center for various clinical studies [10][11].

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle- based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025 Time: 5:00 pm EDT / 1 ...

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle- based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches ...

Core Insights - Nanobiotix presented full results from a Phase 1 study of JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer at the 2025 ESTRO Annual Meeting [1][3] - The study showed promising safety and efficacy outcomes, indicating a potential new treatment option for patients with high unmet needs in this area [5][9] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative nanotherapeutic approaches to enhance cancer treatment outcomes [15][16] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [16] Study Details - The Phase 1 study evaluated JNJ-1900 (NBTXR3) activated by radiotherapy in patients with locally advanced or borderline resectable pancreatic cancer, replacing standard concurrent chemoradiation [3][6] - The study was conducted by The University of Texas MD Anderson Cancer Center, with Dr. Eugene Koay as the principal investigator [1][3] Key Results - The study involved 22 patients, with a median overall survival of 23 months from diagnosis and a median local progression-free survival of 13.3 months from completion of radiation [5][6] - Notable findings included a 59% normalization rate of CA19-9, a biomarker associated with overall survival, and an association between increased circulating tumor mutational burden (cTMB) and improved survival outcomes [5][12] Future Directions - Investigators concluded that further evaluation of JNJ-1900 (NBTXR3) is warranted in a randomized study, with ongoing recruitment for a new cohort combining JNJ-1900 with standard-of-care concurrent chemotherapy [8][9] - The collaboration with MD Anderson aims to explore innovative treatment approaches for patients with high unmet needs in pancreatic cancer [9][14]

Core Viewpoint - Nanobiotix announced the presentation of full results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) for locally advanced or borderline resectable pancreatic cancer, highlighting the potential of its nanoparticle-based therapeutic approach in oncology [1][6]. Group 1: Study Details - The Phase 1 study was conducted by The University of Texas MD Anderson Cancer Center and will be presented by Dr. Eugene Koay at the ESTRO 2025 conference on May 4, 2025 [1][6]. - The study includes both dose escalation and dose expansion phases, focusing on patients who have undergone induction chemotherapy [6]. Group 2: Product Information - NBTXR3 is a novel oncology product made of functionalized hafnium oxide nanoparticles, administered via a one-time intratumoral injection and activated by radiotherapy [4]. - The mechanism of action is designed to induce significant tumor cell death and trigger an adaptive immune response, potentially applicable across various solid tumors treated with radiotherapy [4]. Group 3: Regulatory and Collaboration Efforts - NBTXR3 received a European CE mark in 2019 for soft tissue sarcomas and has been granted Fast Track designation by the FDA for use in locally advanced head and neck squamous cell cancers [5]. - Nanobiotix has engaged in a collaboration with MD Anderson Cancer Center to sponsor multiple studies evaluating NBTXR3 across different tumor types and therapeutic combinations [7]. Group 4: Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve treatment outcomes for cancer patients [8]. - The company was incorporated in 2003 and is headquartered in Paris, France, with additional locations including Cambridge, Massachusetts [9].

Financial Data and Key Metrics Changes - The company reported negative revenue of €7.2 million for 2024, a significant decrease from €36.2 million in 2023, primarily due to the transfer of NanoRay 312 study sponsorship to Johnson & Johnson [36][37] - The net loss attributable to shareholders increased by 72% year-over-year to €68.1 million, or €1.44 per share, compared to a net loss of €39.7 million, or €1.08 per share, in 2023 [40][41] - Cash and cash equivalents decreased to €49.7 million as of December 31, 2024, down from €75.3 million at the end of 2023, but are expected to fund operations into mid-2026 [42] Business Line Data and Key Metrics Changes - The company signed a licensing agreement with Johnson & Johnson, which includes a $20 million milestone payment related to NanoRay 312 progress [28] - R&D expenses totaled €40.5 million for 2024, up from €38.4 million in 2023, driven by increased clinical development activities [39] - Selling, general, and administrative expenses decreased to €20.5 million in 2024 from €22 million in 2023, mainly due to one-off fees incurred in 2023 [40] Market Data and Key Metrics Changes - The collaboration with Johnson & Johnson is expected to address over 100,000 patients in the US and EU5 for lung and head and neck cancers, representing a potential market of €10 billion [11] - The company is actively exploring further financing options, preferably non-dilutive, to extend cash visibility into 2027 [30][88] Company Strategy and Development Direction - The company is focused on advancing its collaboration with Johnson & Johnson and developing its new platform, Curadime, which is expected to be applicable across multiple therapeutic areas [10][22] - The amended licensing agreement with Johnson & Johnson is designed to reduce cash burn and extend the company's cash runway to mid-2026 [29][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for positive data readouts in the near future, particularly for the NanoRay 312 and lung cancer studies [44][48] - The company is in a "de-risked situation" regarding the NBT-XR3 program, with significant progress made in partnerships and clinical development [93] Other Important Information - The company has added two new board observers to its board, indicating ongoing governance improvements [25] - The company is working on its internal pipeline and has signed multiple Material Transfer Agreements (MTAs) with biotech and pharma companies [97] Q&A Session Summary Question: Details on the phase two CONVERGE study by J&J - Management stated that the trial has started and is progressing well, but specific timelines for initial data are not yet available [54][55] Question: Upcoming pancreatic cancer data presentation - The upcoming data will include full efficacy and safety results, as well as potential biomarkers, which were not detailed in the previous press release [58][59] Question: Remaining costs for the NanoRay study - The remaining costs are relatively immaterial, with the majority now covered by Johnson & Johnson, and any future payments expected to be in the single-digit millions [65][69] Question: Recent communication with the FDA - Management reported no delays in meetings or interactions with the FDA, indicating that the program is well engaged [67] Question: Long-term R&D initiatives beyond NBT-XR3 - Management highlighted the Curadime platform as a key area for future development, alongside ongoing work on the NBT-XR3 program [73][76]

Financial Performance - The company has incurred losses totaling €380.4 million since inception, with a net loss of €68.1 million for the year ended December 31, 2024[102]. - As of December 31, 2024, the company had cash and cash equivalents of €49.7 million[102]. - The company anticipates continuing to incur significant losses for the foreseeable future due to ongoing clinical studies and development expenses related to its product candidates[103]. - The company has not yet established a source of revenue sufficient to cover its operating costs, relying instead on capital increases and collaboration agreements[104]. - The company expects near-term losses and cash utilization to stabilize or slightly decrease due to amendments in the Janssen Agreement[97]. - The company may face challenges in raising additional funding, which could materially affect its operations and financial position[105]. - The company may face dilution of current ownership interests if additional capital is raised through equity or convertible securities[108]. - Debt financing could lead to increased fixed payment obligations and may impose restrictive covenants affecting operational flexibility[108]. - The company has entered into loan agreements with the European Investment Bank, Bpifrance Financement, and HSBC France, which could impact financial stability if payment defaults occur[110]. - Failure to obtain timely funding may result in significant delays or discontinuation of research and development programs[111]. Competition and Market Risks - The company faces substantial competition from other biotechnology and pharmaceutical companies, many of which have greater resources and experience[99]. - The company may face difficulties in achieving market acceptance for NBTXR3, even if it receives regulatory approval[153]. - The ability to penetrate global markets is crucial for future profitability, dependent on Janssen's commitment and resource allocation[159]. - Legislative and political uncertainties could adversely affect the ability to market products and generate revenues[257]. Clinical Development Challenges - The development of product candidates is subject to high attrition rates, with no assurance of success at any stage[113]. - The complexity of the nanotechnology used in product candidates like NBTXR3 may lead to unpredictable development timelines and costs[125]. - Manufacturing processes for NBTXR3 are highly regulated and subject to risks that could impact production and supply[129]. - Difficulty in patient enrollment for clinical studies could delay regulatory approval and commercialization timelines[136]. - Changes in manufacturing processes may require additional regulatory approvals, potentially delaying product development[135]. - The company faces challenges in patient enrollment for clinical trials due to competition and limited qualified investigators, which may delay or terminate studies[138]. - Delays in patient enrollment could lead to increased costs and affect the timing of clinical trials, potentially hindering product development[140]. - Undesirable side effects from product candidates could interrupt clinical trials and delay regulatory approvals, impacting market acceptance[141]. - The company relies on third parties for various aspects of development, which may lead to risks if these parties do not perform satisfactorily[171]. Regulatory and Compliance Issues - The regulatory landscape for the company's product candidates, particularly NBTXR3, is complex and may lead to unexpected costs or delays in obtaining necessary marketing authorizations[227][228]. - NBTXR3 is classified as a Class III medical device in the EU and as a drug in the U.S., requiring compliance with different regulatory frameworks that may extend the development timeline and increase costs[229]. - The company must provide regulatory authorities with data demonstrating the safety and efficacy of its product candidates before they can be marketed, which adds to the complexity of the approval process[230]. - Delays or failures in obtaining marketing authorization or CE-marking could significantly decrease the company's ability to generate product revenue[231]. - The approval processes for product candidates, including NBTXR3, are lengthy, expensive, and unpredictable, potentially harming the business if regulatory approval is not obtained[232]. - Regulatory authorities may impose limitations on approved products, including restrictions on marketing, labeling, and the need for costly post-marketing clinical trials[237]. - The company received Fast Track designation from the FDA for NBTXR3 in February 2020 for treating locally advanced head and neck squamous cell cancer, but this does not guarantee a faster approval process[244]. - Regulatory compliance is critical post-approval, and failure to meet requirements could lead to significant penalties, including suspension or withdrawal of marketing authorization[239]. - The company is subject to extensive healthcare laws and regulations, which could lead to significant civil, criminal, and administrative penalties if found non-compliant[263]. Strategic Partnerships and Licensing - A global exclusive licensing agreement with Janssen is critical for the commercialization of NBTXR3, with future payments expected to contribute significantly to revenue[165]. - The company transferred the sponsorship of the NANORAY-312 clinical trial to Janssen, increasing reliance on Janssen for successful execution[166]. - The company’s reliance on Janssen limits its ability to pursue additional studies or collaborations in oncology, amplifying associated risks[167]. - The company has strategic licensing agreements, including the Janssen Agreement, which grants worldwide development and commercialization rights for product candidate NBTXR3[180]. - The company faces risks if strategic licensees do not effectively pursue product candidates, potentially impacting revenue streams from milestone and royalty payments[181]. Operational and Management Risks - The company has identified a material weakness in internal control over financial reporting, which could adversely affect investor confidence[204]. - The company identified material weaknesses in internal control over financial reporting for the years ended December 31, 2022, and December 31, 2023, due to insufficient supervisory personnel with appropriate technical accounting experience[206]. - Remediation plans have been implemented to address these material weaknesses, but the effectiveness of these controls cannot be assured for the year ending December 31, 2024[207]. - The company may face limitations in preventing or detecting misstatements in financial statements, which could impact compliance with securities law and investor confidence[208]. - Compliance with Section 404 will incur substantial accounting expenses and management attention, with independent auditors required to attest to the effectiveness of internal controls starting with the annual report for the year ending December 31, 2025[209]. - The company may face difficulties in managing growth and expansion, which could disrupt operations and increase expenses[195]. - The company must share trade secrets with third parties, increasing the risk of unauthorized disclosure or misappropriation[188]. Supply Chain and Manufacturing Risks - The company is dependent on third parties for the supply of materials necessary for product candidates, which could be interrupted, affecting development and commercialization timelines[184]. - The company faces risks related to potential interruptions in supply from approved manufacturers, which could disrupt clinical and commercial supply chains[270]. - The company must ensure that all third-party manufacturers adhere to regulatory requirements to avoid sanctions that could disrupt operations[267]. - The company’s product candidates, including NBTXR3, are subject to rigorous quality control measures to prevent contamination and ensure stability[266]. - Manufacturing facilities, including the in-house facility in Villejuif, France, must comply with stringent cGMP and ISO13485 regulations, which may increase operational costs and complexity[265][269]. Insurance and Liability - The company maintains product liability insurance, but coverage may be insufficient to cover potential claims, impacting financial stability[199]. - Non-compliance with healthcare laws could result in exclusion from government-funded healthcare programs, significantly impacting revenue streams[263].

[Business and Operational Update](index=1&type=section&id=Business%20and%20Operational%20Update) Nanobiotix highlights significant progress in its global development program for JNJ-1900 (NBTXR3) and strengthened its financial position [Operational Highlights](index=1&type=section&id=Operational%20Highlights) Nanobiotix made significant progress in JNJ-1900 development, improved financial stability, and launched a new nanotherapeutic platform - The global development program for JNJ-1900 (NBTXR3) is proceeding as planned, targeting major oncology markets like head and neck and lung cancer[4](index=4&type=chunk) - A disciplined financial strategy has extended the company's cash runway into **mid-2026**, with **€49.7 million** in cash and cash equivalents as of December 31, 2024[4](index=4&type=chunk) - The company has launched Curadigm, a next-generation nanotherapeutic platform designed to enhance drug development across various therapeutic areas[4](index=4&type=chunk) - Clinical data readouts are expected in **2025** from Phase 1 and 2 studies in several cancers, including RM-HNSCC, pancreatic cancer, and NSCLC[4](index=4&type=chunk) [JNJ-1900 (NBTXR3) Development Program](index=1&type=section&id=JNJ-1900%20(NBTXR3)%20Development%20Program) JNJ-1900 development advanced with NANORAY-312 sponsorship transfer and first patient dosing in the CONVERGE study - The sponsorship of the pivotal Phase 3 NANORAY-312 study for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) was transferred to Johnson & Johnson in the US in Q4 2024, with a global transfer intended by Q3 2025[5](index=5&type=chunk) - The first patient was dosed in the Johnson & Johnson-sponsored Phase 2 CONVERGE study in Q1 2025, evaluating JNJ-1900 for unresectable stage 3 non-small cell lung cancer (NSCLC)[5](index=5&type=chunk) - A Phase 1 study in pancreatic cancer was completed, and a new cohort was launched to evaluate JNJ-1900 combined with standard-of-care chemoradiation (CCRT)[5](index=5&type=chunk)[8](index=8&type=chunk) - The dose escalation part of a Phase 1 study in NSCLC amenable to re-irradiation was completed, establishing the recommended Phase 2 dose and showing a favorable safety profile[8](index=8&type=chunk) [Financial Strategy and Other Highlights](index=2&type=section&id=Financial%20Strategy%20and%20Other%20Highlights) Nanobiotix strengthened its financial position and extended cash runway through strategic agreements and launched the Curadigm platform - Received a **$20 million** milestone payment from Johnson & Johnson in May 2024 related to the NANORAY-312 study[8](index=8&type=chunk) - Amended the global licensing agreement for JNJ-1900 in Q1 2025, removing the majority of Nanobiotix's funding obligation for NANORAY-312 and extending the cash runway to **mid-2026**[8](index=8&type=chunk) - Launched the Curadigm Nanoprimer Platform in Q4 2024, a technology designed to increase the bioavailability and tissue accumulation of intravenously administered medicines[8](index=8&type=chunk) - Strengthened the Supervisory Board with the nomination of two board observers, Dr. Margaret A. Liu and Ms. Anat Naschitz, to support long-term growth[8](index=8&type=chunk) [Full Year 2024 Financial Results](index=3&type=section&id=Full%20Year%202024%20Financial%20Results) Nanobiotix reported a net loss increase in FY2024, primarily due to a non-cash revenue adjustment, while managing expenses and cash position [Financial Performance Summary](index=3&type=section&id=Financial%20Performance%20Summary) FY2024 saw negative revenue due to a non-cash adjustment, increased R&D expenses, decreased SG&A, and a higher net loss FY 2024 Financial Performance vs. FY 2023 (€ millions) | Metric | FY 2024 | FY 2023 | Change | | :--- | :--- | :--- | :--- | | Total revenues and other income | (7.2) | 36.2 | N/A | | R&D Expenses | (40.5) | (38.4) | +5.5% | | SG&A Expenses | (20.5) | (22.0) | -6.8% | | Net Loss | (68.1) | (39.7) | +71.5% | | Loss per Share (€) | (1.44) | (1.08) | +33.3% | - Negative revenue of **€7.2 million** was primarily caused by a one-time, non-cash negative revenue impact of **€19.3 million** from the transfer of NANORAY-312 study sponsorship to Janssen, based on IFRS 15 accounting principles[9](index=9&type=chunk) - The **5% increase** in R&D expenses was mainly due to increased clinical development activities for the NANORAY-312 and Study 1100 trials[10](index=10&type=chunk) - The **7% decrease** in SG&A expenses resulted from one-off legal and financial advisory fees incurred in 2023 related to the license agreement and equity issuance[11](index=11&type=chunk) [Financial Position and Guidance](index=3&type=section&id=Financial%20Position%20and%20Guidance) Nanobiotix maintained a strong cash position of **€49.7 million** as of December 31, 2024, extending its cash runway into mid-2026 - Cash and cash equivalents stood at **€49.7 million** as of December 31, 2024, compared to **€75.3 million** at the end of 2023[13](index=13&type=chunk) - The company anticipates its current cash position will fund operations into **mid-2026**[13](index=13&type=chunk)[15](index=15&type=chunk) - The amended agreement with Johnson & Johnson provides a non-dilutive financing solution that is expected to reduce operational burn immediately and moving forward[15](index=15&type=chunk) [About Nanobiotix and NBTXR3 (JNJ-1900)](index=4&type=section&id=About%20Nanobiotix%20and%20NBTXR3%20(JNJ-1900)) This section provides an overview of Nanobiotix as a company and details its lead product, NBTXR3 (JNJ-1900) [About NBTXR3 (JNJ-1900)](index=4&type=section&id=About%20NBTXR3%20(JNJ-1900)) NBTXR3 (JNJ-1900) is a novel, physics-based radioenhancer for oncology, currently in a pivotal Phase 3 study for head and neck cancer - NBTXR3 is a physics-based radioenhancer composed of functionalized hafnium oxide nanoparticles, administered via a one-time intratumoral injection and activated by radiotherapy[19](index=19&type=chunk) - Its mechanism of action is designed to cause significant tumor cell death, which in turn triggers an adaptive immune response and long-term anti-cancer memory[19](index=19&type=chunk) - The lead clinical program is NANORAY-312, a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers, with FDA Fast Track designation for this indication[20](index=20&type=chunk) - Nanobiotix has a global co-development and commercialization license agreement for NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company[21](index=21&type=chunk) [About Nanobiotix](index=4&type=section&id=About%20Nanobiotix) Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches, listed on Euronext Paris and Nasdaq - Nanobiotix is a late-stage clinical biotechnology company focused on disruptive, physics-based therapeutic approaches[22](index=22&type=chunk) - The company was incorporated in **2003**, is headquartered in Paris, France, and is listed on Euronext Paris and Nasdaq[23](index=23&type=chunk) - It owns over **25 patent families** associated with three nanotechnology platforms with applications in oncology, bioavailability, and central nervous system disorders[25](index=25&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) This section presents the company's consolidated financial statements, including operations and financial position, for 2024 and 2023 [Statements of Consolidated Operations](index=5&type=section&id=Statements%20of%20Consolidated%20Operations) This section presents the company's consolidated statements of operations for the years ended December 31, 2024, and 2023, detailing revenues, expenses, and net loss Statements of consolidated operations (Amounts in thousands of euros) | | For the year ended December 31, | | :--- | :--- | :--- | | | **2024** | **2023** | | **Revenues and other income** | | | | Revenues | (11,609) | 30,058 | | Other income | 4,419 | 6,150 | | **Total revenues and other income** | **(7,191)** | **36,207** | | Research and development expenses | (40,541) | (38,396) | | Selling, general and administrative expenses | (20,527) | (22,049) | | Other operating and income expenses | (134) | (2,542) | | **Total operating expenses** | **(61,202)** | **(62,986)** | | **Operating income (loss)** | **(68,392)** | **(26,779)** | | Financial income | 7,849 | 2,002 | | Financial expenses | (7,488) | (14,803) | | **Financial income (loss)** | **361** | **(12,801)** | | Income tax | (101) | (120) | | **Net loss for the period** | **(68,132)** | **(39,700)** | | Basic loss per share (euros/share) | (1.44) | (1.08) | | Diluted loss per share (euros/share) | (1.44) | (1.08) | [Statements of Consolidated Financial Position](index=6&type=section&id=Statements%20of%20Consolidated%20Financial%20Position) This section provides the company's consolidated statements of financial position as of December 31, 2024, and 2023, outlining assets, liabilities, and shareholders' equity Statements of consolidated financial position (Amounts in thousands of euros) | | As of December 31, | | :--- | :--- | :--- | | | **2024** | **2023** | | Total non-current assets | 5,951 | 6,558 | | Cash and cash equivalents | 49,737 | 75,283 | | Total current assets | 61,466 | 87,339 | | **TOTAL ASSETS** | **67,418** | **93,897** | | Total shareholders' equity | (65,704) | (1,843) | | Total non-current liabilities | 74,187 | 45,866 | | Total current liabilities | 58,934 | 49,873 | | **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | **67,418** | **93,897** |

Core Insights - Nanobiotix, a late-stage clinical biotechnology company, is set to report its financial results for Q4 and the full year of 2024 on April 2, 2025, after the U.S. market closes [1] - A conference call and webcast will follow on April 3, 2025, at 8:00 AM EDT, where the CEO and CFO will discuss year-end results and business updates [2] Company Overview - Nanobiotix is headquartered in Paris, France, and has been listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [5] - The company focuses on nanoparticle-based therapeutic approaches, particularly in oncology, bioavailability, and central nervous system disorders [5] - Nanobiotix holds over 25 patent families related to its three nanotechnology platforms [5]